Please assess the completion status of the following clinical trial:

Trial Title: Empower Neuromodulation System - Pilot Study for Anxiety Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥19 years old~* Current diagnosis of GAD per DSM-5 via M.I.N.I. assessment by clinician~* Hamilton Anxiety Rating Scale (HAM-A) ≥18~* Negative urine pregnancy test at screening (females only)~* Able to provide informed consent~* Capable and willing to follow all study-related procedures~Exclusion Criteria:~* Has current (past 30 days) psychotic or bipolar disorder, homicidal ideation, psychiatric hospitalization, or moderate/severe substance use disorders per clinician assessment via M.I.N.I.~* Hamilton Depression Rating Scale (HAM-D) ≥18~* PTSD Checklist for DSM-5 (PCL-5) ≥51~* Exhibits suicidal intent as confirmed on the Columbia-Suicide Severity Rating Scale-Revised (C-SSRS-R) with a Yes response to question 4 or question 5 or to question 6 in the past 3 months.~* Changes in psychoactive medications in the past 30 days (including but not limited to psychotropic medications, thyroid hormone medication, steroids), with the exception of benzodiazepines~* If regularly taking benzodiazepines, has had changes in benzodiazepine dosing in the past 30 days or average use \>2 days per week~* Psychotherapy was initiated or discontinued in the past 30 days or psychotherapy modality was changes in the past 30 days~* Has a history of epilepsy or a seizure disorder~* Has been diagnosed with peripheral nerve damage of the arm or hand or has numbness or tingling in the arm or hand at least weekly~* Is currently pregnant or breastfeeding, has been pregnant within the past 6 months or intends to become pregnant during the study period~* Currently has an active implant and/or an electrical or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator, bone growth stimulator, or cochlear implant~* Has an electrically conductive metal object (e.g. jewelry) that cannot be removed from the upper extremities and will directly contact the gel electrodes of the Empower Neuromodulation System at the active or sham anatomic location~* Has an open incision, wound, scar, active infection or otherwise compromised skin that will directly contact the gel electrodes of the Empower Neuromodulation System at either the active or sham anatomic location~* Does not have daily access to an electrical outlet for charging the investigational device and associated smartphone~* Has used of an investigational drug/device therapy within the past four weeks~* Unable to provide informed written consent~* Has any medical condition that would, in the opinion of the investigator, make the participant ineligible

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): Participants will self-administer treatment with the Empower device at the active treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower active treatment.
- Sham treatment (Type: SHAM_COMPARATOR): Participants will self-administer treatment with the Empower device at the sham treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower sham treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues